<p>In this episode, Contributing Editor Brian Hill, MD, PhD, speaks with Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center in New York. Their conversation focuses on Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia.</p>

In this episode, Contributing Editor Brian Hill, MD, PhD, speaks with Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center in New York. Their conversation focuses on Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia.

Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.

Share Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia

Sign up to save your podcasts

Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia

Continuous Versus Fixed-Duration Treatment for Frontline Chronic Lymphocytic Leukemia

More shows like The Hematologist

Research To Practice | Oncology Videos

Treating Blood Cancers

EHA Unplugged

WolverHeme Happy Hour